There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Beam Therapeutics (BEAM – Research Report), KalVista Pharmaceuticals (KALV – Research Report) and Cue Biopharma (CUE – Research Report) with bullish sentiments.
Beam Therapeutics (BEAM)
In a report released today, Sami Corwin from William Blair maintained a Buy rating on Beam Therapeutics. The company’s shares closed last Monday at $21.47, close to its 52-week low of $16.95.
According to TipRanks.com, Corwin has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Beam Therapeutics with a $43.40 average price target, a 105.0% upside from current levels. In a report issued on October 31, Wells Fargo also maintained a Buy rating on the stock with a $75.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
KalVista Pharmaceuticals (KALV)
In a report released today, Serge Belanger from Needham maintained a Buy rating on KalVista Pharmaceuticals, with a price target of $22.00. The company’s shares closed last Monday at $7.59.
According to TipRanks.com, Belanger has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for KalVista Pharmaceuticals with a $21.00 average price target.
Cue Biopharma (CUE)
In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Cue Biopharma, with a price target of $15.00. The company’s shares closed last Monday at $2.31.
According to TipRanks.com, Benjamin has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cue Biopharma with a $11.50 average price target, a 395.7% upside from current levels. In a report issued on November 6, Piper Sandler also reiterated a Buy rating on the stock with a $8.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BEAM:
- Beam Therapeutics price target lowered to $26 from $35 at Barclays
- Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
- Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
- Beam Therapeutics reports Q3 EPS ($1.22), consensus ($1.35)
- BEAM Earnings this Week: How Will it Perform?
